Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity.
Alexandre A da Costa, Ozge Somuncu, Ramya Ravindranathan...
https://pubmed.ncbi.nlm.nih.gov/38885312/Actively Recruiting
Led by Exelixis · Updated on 2025-09-05
429
Participants Needed
16
Research Sites
30 weeks
Total Duration
Researchers are evaluating XL309 previously ISM3091, alone and in combination with olaparib, in participants with advanced solid tumors. This first-in-human, multicenter, open-label Phase I trial aims to assess the safety, tolerability, preliminary antitumor activity, as well as how the body processes and responds to XL309 in these patients. The study is sponsored by Exelixis and targets advanced cancers that have progressed despite standard treatments or have no current therapies available. The study includes a Dose Escalation Stage where participants receive increasing doses of XL309 alone or combined with olaparib. Following this, a Cohort Expansion Stage will further study the recommended dose in specific advanced solid tumor groups both as a single agent and in combination. Both drugs are given orally according to assigned schedules in sequential cohorts. The trial is non-randomized and open-label, meaning all participants know which treatment they are receiving. Participants will undergo safety monitoring for treatment-related adverse events, dose-limiting toxicities, and laboratory abnormalities over approximately 24 months. Researchers will also measure drug levels in the blood and tumor response rates. Eligibility includes adults with specific genetic alterations related to their cancer type, adequate organ function, and performance status. The study excludes those with recent anticancer treatments, untreated brain metastases, or certain health conditions. Participants may be followed for up to several years to evaluate safety and preliminary efficacy.
CONDITIONS
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
E
Exelixis Clinical Trials
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Exelixis
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational XL309 therapy | Olaparib maintenance (current standard) |
|---|---|---|
| What it is | An investigational oral USP1 inhibitor (XL309), tested alone or combined with olaparib in adults with HRR‑altered advanced solid tumors. | Maintenance therapy using olaparib in biomarker‑selected HRR‑mutated tumors (e.g., platinum‑sensitive ovarian cancer) is an established current-care option. |
| Role in the trial | Evaluational regimen administered sequentially for dose escalation and expansion. | Not part of this study design, shown for clinical context only. |
| Primary use | To determine safety, tolerability, pharmacokinetics, pharmacodynamics and initial signs of activity of XL309, alone and combined with olaparib, in HRR‑altered advanced solid tumors. | Used as maintenance therapy to prolong progression‑free intervals in HRD‑positive or BRCA‑mutated ovarian cancer following response to platinum chemotherapy. |
| How it is given or performed | XL309 is given orally, either alone or in combination with oral olaparib per assigned dosing schedule. | Olaparib is administered orally as maintenance therapy following response to platinum chemotherapy. |
| Evidence status | Early‑stage trial; activity signals and safety are under investigation. | Randomized trials and meta‑analyses show olaparib improves progression‑free survival in HRD or BRCA‑mutated ovarian cancer. |
| Important risks | Safety profile of XL309 is not yet established. | Olaparib is associated with higher risk of grade 3 or higher adverse events and rare haematologic toxicities. |
| Important limitations | As a first‑in‑human sequential phase I study, limited data are available on efficacy and long‑term safety. | Benefit has been most established in ovarian cancer; extrapolation to other HRR‑mutated solid tumors remains uncertain. |
| Patient impact | Not yet established; outcomes are under investigation. | Olaparib maintenance significantly prolongs time before disease progression for HRD‑positive or BRCA‑mutated ovarian cancer patients. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 24 months
Participants receive XL309 alone or in combination with olaparib orally per assigned dosing schedule to evaluate safety, tolerability, and preliminary efficacy.
Regular visits according to dosing schedule
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Alexandre A da Costa, Ozge Somuncu, Ramya Ravindranathan...
https://pubmed.ncbi.nlm.nih.gov/38885312/Exelixis
Lead Sponsor